Completed PHASE2/PHASE3 INTERVENTIONAL 1-arm NCT01315795

Lanreotide Autogel in the Treatment of Symptomatic Polycystic Liver Disease (LOCKCYST)

An Open-label, Phase II Clinical Study to Evaluate the Efficacy and Safety of Lanreotide Autogel 90mg Every 4 Weeks in the Treatment of Symptomatic Polycystic Liver Disease, Including a Dose Escalation at Month 6 to Lanreotide Autogel 120mg for Non Responders

Sponsor: Ipsen

Conditions Polycystic Liver Disease

Interventions Lanreotide Autogel 90 mg and 120 mg

Updated 6 times since 2017 Last updated: Jul 7, 2014 Started: Mar 31, 2011 Primary completion: Jul 31, 2014 Completion: Jul 31, 2014

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2/PHASE3 clinical study on Polycystic Liver Disease, this trial is completed. The trial is conducted by Ipsen and has accumulated 6 data snapshots since 2011. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2/PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2/PHASE3

Phase: PHASE2_PHASE3 → PHASE2/PHASE3
Nov 2022 — Jul 2024 [monthly]

Completed PHASE2_PHASE3
Jan 2021 — Nov 2022 [monthly]

Completed PHASE2_PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2_PHASE3

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Completed PHASE2_PHASE3

First recorded

Mar 2011

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Ipsen
Universitaire Ziekenhuizen KU Leuven

Data source: Universitaire Ziekenhuizen KU Leuven

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Leuven, Belgium